These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 38747974)

  • 1. Arming Vδ2 T Cells with Chimeric Antigen Receptors to Combat Cancer.
    Thomas P; Paris P; Pecqueur C
    Clin Cancer Res; 2024 Aug; 30(15):3105-3116. PubMed ID: 38747974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
    Hong M; Clubb JD; Chen YY
    Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.
    Mirzaei HR; Mirzaei H; Lee SY; Hadjati J; Till BG
    Cancer Lett; 2016 Oct; 380(2):413-423. PubMed ID: 27392648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of gamma/delta T cells for solid tumor immunotherapy.
    Zhu D; Ren X; Xie W; Chen J; Liang S; Jiang M; Wang J; Zheng Z
    Front Immunol; 2024; 15():1466266. PubMed ID: 39253082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward.
    Jafarzadeh L; Masoumi E; Fallah-Mehrjardi K; Mirzaei HR; Hadjati J
    Front Immunol; 2020; 11():702. PubMed ID: 32391013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the power of Vδ2 cells in cancer immunotherapy.
    Fowler DW; Bodman-Smith MD
    Clin Exp Immunol; 2015 Apr; 180(1):1-10. PubMed ID: 25469879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Making CAR T Cells a Solid Option for Solid Tumors.
    Schmidts A; Maus MV
    Front Immunol; 2018; 9():2593. PubMed ID: 30467505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Car T Cells in Solid Tumors: Overcoming Obstacles.
    Rojas-Quintero J; Díaz MP; Palmar J; Galan-Freyle NJ; Morillo V; Escalona D; González-Torres HJ; Torres W; Navarro-Quiroz E; Rivera-Porras D; Bermúdez V
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
    Wagner J; Wickman E; DeRenzo C; Gottschalk S
    Mol Ther; 2020 Nov; 28(11):2320-2339. PubMed ID: 32979309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.
    Wang Z; Zhou L; Wu X
    Oncol Res; 2024; 32(9):1479-1516. PubMed ID: 39220130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene modification strategies for next-generation CAR T cells against solid cancers.
    Tian Y; Li Y; Shao Y; Zhang Y
    J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.